<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-0754</journal-id>
<journal-title><![CDATA[Nascer e Crescer]]></journal-title>
<abbrev-journal-title><![CDATA[Nascer e Crescer]]></abbrev-journal-title>
<issn>0872-0754</issn>
<publisher>
<publisher-name><![CDATA[Centro Hospitalar do Porto]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-07542022000300241</article-id>
<article-id pub-id-type="doi">10.25753/birthgrowthmj.v31.i3.27540</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[SARS-CoV-2 infection in children with cystic fibrosis: Experience of a Portuguese reference centre]]></article-title>
<article-title xml:lang="pt"><![CDATA[Infeção por SARS-CoV-2 em crianças com fibrose quística: Experiência de um centro de referência português]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[Mafalda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Patrícia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Catarino]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[Inês]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A5 "/>
<xref ref-type="aff" rid="Af6"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar do Tâmega e Sousa Department of Pediatrics ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Senhora da Oliveira Department of Pediatrics ]]></institution>
<addr-line><![CDATA[Guimarães ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Hospitalar Universitário de São João Autonomous Unit for the Management of Women and Children Department of Pediatrics]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina Department of Gynecology-Obstetrics and Pediatrics]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidade do Porto EPIUnit - Instituto de Saúde Pública ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidade do Porto Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR) ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>31</volume>
<numero>3</numero>
<fpage>241</fpage>
<lpage>246</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-07542022000300241&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-07542022000300241&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-07542022000300241&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction Respiratory viruses are often responsible for pulmonary exacerbations and increased morbimortality in patients with cystic fibrosis (CF). For this reason, SARS-CoV-2 was expected to have a significant impact on the respiratory status of these patients, especially in those at risk. Detailed data of the clinical course of COVID-19 in children with CF is scarce.  Objectives:  The aim of this study was to determine the incidence, clinical characteristics, and course of COVID-19 infection in pediatric patients with CF.  Material and methods: This was a retrospective observational study of children with CF and SARS-CoV-2 infection followed at a Portuguese reference centre between March 2020 and March 2022.  Results: Twelve of 30 children with CF were infected by SARS-CoV-2 (40%), in a total of 13 episodes. The median age was 10.5 years, and 33% were male. Most cases (69%) occurred between January and March 2022, when Omicron was the predominant variant. The infection rate was higher in children not fully vaccinated. None of the children with additional risk factors was infected. Ninety-two percent of patients presented with mild disease and one child with low body mass index was hospitalized with pneumonia. None required oxygen therapy or admission to the Intensive Care Unit. No cases of mortality were reported. Eighty-three percent of patients fully recovered after two months of follow-up.  Discussion: In this first national study of children with CF and COVID-19 infection, most children presented with mild disease and could be safely managed at home.  Conclusion: This study is in line with the few evidence available in the literature and contributes to a better understanding of SARS-CoV-2 infection in children with CF during predominance of the Omicron variant, providing additional data that can guide families and clinical teams in the management of patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: Dado que os vírus são frequentemente responsáveis por exacerbações respiratórias e aumento da morbimortalidade em doentes com fibrose quística (FQ), seria expetável que a infeção por SARS-CoV-2 tivesse um impacto significativo na condição respiratória destes doentes, sobretudo nos de risco elevado. Atualmente, o conhecimento acerca da evolução clínica da COVID-19 em crianças com FQ é escasso.  Objetivo:  O objetivo deste estudo foi avaliar a incidência, apresentação clínica e evolução da COVID-19 em doentes pediátricos com FQ.  Materiais e Métodos: Este foi um estudo retrospetivo de crianças com FQ e infeção por SARS-CoV-2 seguidas num centro de referência português entre março de 2020 e março de 2022.  Resultados: Doze de 30 crianças com FQ foram infetadas por SARS-CoV-2 (40%), num total de 13 episódios. A mediana de idades foi de 10.5 anos e 33% eram rapazes. A maioria dos casos (69%) ocorreu entre janeiro e março de 2022, durante a predominância da variante Omicron. A taxa de infeção foi superior em crianças com vacinação incompleta. Nenhum dos doentes com fatores de risco adicionais foi infetado. Noventa e dois por cento das crianças apresentaram doença ligeira e um adolescente com baixo índice de massa corporal foi hospitalizado por pneumonia. Nenhum necessitou de oxigenoterapia ou internamento em Unidade de Cuidados Intensivos. A mortalidade foi nula. Oitenta e três porcento dos doentes apresentou recuperação completa após dois meses de seguimento.  Discussão:  Neste primeiro estudo nacional de crianças com FQ e COVID-19, a maioria apresentou doença ligeira e pode ser adequadamente seguida em ambulatório.  Conclusão: Este estudo está de acordo com os poucos dados disponíveis na literatura e contribui para aumentar o conhecimento da infeção por SARS-CoV-2 em crianças com FQ. Essa informação permitirá uma melhor orientação destes doentes por parte das famílias e equipas clínicas que os seguem.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[child]]></kwd>
<kwd lng="en"><![CDATA[coronavirus]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[cystic fibrosis]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[criança]]></kwd>
<kwd lng="pt"><![CDATA[coronavírus]]></kwd>
<kwd lng="pt"><![CDATA[COVID-19]]></kwd>
<kwd lng="pt"><![CDATA[fibrose quística]]></kwd>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Páez-Velásquez]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Uribe]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Castilla-Peón]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Lezana-Fernández]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS-CoV-2 infection in a pediatric patient with cystic fibrosis]]></article-title>
<source><![CDATA[Bol Med Hosp Infant Mex]]></source>
<year>2021</year>
<volume>78</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-33</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burgel]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Gartner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[van Koningsbruggen-Rietschel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naehrlich]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sermet-Gaudelus]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Southern]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of COVID-19 on people with cystic fibrosis]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2020</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e35-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Yazidi]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Al Maskari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Al Reesi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Children with cystic fibrosis hospitalised with covid-19 multicentre experience]]></article-title>
<source><![CDATA[J Paediatr Child Health]]></source>
<year>2021</year>
<volume>57</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>767-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cosgriff]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zampoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elbert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burgel]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis An international observational study]]></article-title>
<source><![CDATA[J Cyst Fibros]]></source>
<year>2021</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosgriff]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ahern]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Brownlee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Burgel]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Byrnes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Registry Harmonization Group A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis]]></article-title>
<source><![CDATA[J Cyst Fibros]]></source>
<year>2020</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>355-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleming-Dutra]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Britton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Derado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Link-Gelles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Accorsi]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2022</year>
<volume>327</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2210-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>DGS</collab>
<source><![CDATA[Norma nº 004/2020 de 23/03/2020 atualizada a 05/01/2022 - Abordagem das Pessoas com Suspeita ou Confirmação de COVID-19]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[TWR]]></given-names>
</name>
<name>
<surname><![CDATA[Brownlee]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Denton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Littlewood]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients]]></article-title>
<source><![CDATA[J Cystic Fibros]]></source>
<year>2003</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-34</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
